Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies...
AbstractMonoclonal antibodies (mAbs) are increasingly used to treat rheumatoid arthritis (RA). At present, anti-tumor necrosis factor-α drugs (infliximab, adalimumab, certolizumab pegol, and...
View ArticleBevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival...
AbstractObjectiveClinical response to bevacizumab varies between patients treated for metastatic colorectal cancer (mCRC). The aim of this study was to quantify individual factors affecting bevacizumab...
View ArticlePharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic...
AbstractThe combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients...
View ArticleA possible association of baseline serum IL-17A concentrations with...
AbstractBackgroundColorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in...
View ArticleInfluence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on...
AbstractBackground and objectivesRituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows...
View ArticleRevisiting myocardial necrosis biomarkers: assessment of the effect of...
AbstractInfarct size is a major predictor of subsequent cardiovascular events following ST-segment elevation myocardial infarction (STEMI) and is frequently used in clinical trials focused on...
View ArticleA novel way to manage trastuzumab cardiotoxicity
AbstractPurposeTrastuzumab is the most widely prescribed anti-HER2 humanized monoclonal antibody. Cardiac toxicity is the only limiting toxicity of trastuzumab and it is of particular concern in...
View ArticleModel-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum...
AbstractBackground and ObjectivesThe pharmacokinetics of infliximab are highly variable and influence clinical response in chronic inflammatory diseases. The goal of this study was to build a Bayesian...
View Article17p deletion strongly influences rituximab elimination in chronic lymphocytic...
AbstractChronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this...
View ArticleInfluence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies...
AbstractTherapeutic antibodies are increasingly used to treat various diseases, including neoplasms and chronic inflammatory diseases. Antibodies exhibit complex pharmacokinetic properties, notably...
View ArticleA successful compartmental approach for the treatment of breast cancer brain...
AbstractBackgroundBrain metastases are challenging daily practice in oncology and remain a compartmental problem since most anti-cancer drugs do not cross the blood–brain barrier at relevant...
View ArticleModelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal...
AbstractTherapeutic monoclonal antibodies (mAbs) are increasingly used to treat a variety of conditions. The sources of their interindividual pharmacokinetic (PK) variability have been extensively...
View ArticleNon-Linear Rituximab Pharmacokinetics and Complex Relationship between...
AbstractBackground and ObjectivesRituximab is approved in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and leads to a decrease of ANCA levels. The objectives of...
View ArticleInfliximab Treatment Does Not Lead to Full TNF-α Inhibition: A...
AbstractBackground and ObjectiveInfliximab, an anti-tumour necrosis factor (TNF)-α monoclonal antibody, has been approved in chronic inflammatory disease, including rheumatoid arthritis, Crohn’s...
View ArticleRelationship Between Antithymocyte Globulin Concentrations and Lymphocyte...
AbstractBackgroundRabbit antithymocyte globulins (rATGs) are polyclonal antibodies used to prevent acute cellular rejection in kidney transplantation. Their dosing remains largely empirical and the...
View ArticleThe Influence of Underlying Disease on Rituximab Pharmacokinetics May be...
AbstractBackground and ObjectivesRituximab is an anti-CD20 monoclonal antibody approved in several diseases, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL),...
View ArticleRelationship Between Cetuximab Target-Mediated Pharmacokinetics and...
AbstractBackground and ObjectiveCetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal cancer...
View Article
